ANGLE plc (GB:AGL) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ANGLE plc has entered into an agreement with NuProbe to attain an exclusive license for a next-generation sequencing (NGS) assay, enhancing the capabilities of its liquid biopsy technology, Parsortix. The NGS panel, which facilitates the analysis of both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample, promises to advance cancer treatment personalization. This collaboration aims to bolster ANGLE’s pharma services and offer clinicians tools for ongoing monitoring of tumor dynamics and patient response to therapies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue